<DOC>
	<DOC>NCT01010399</DOC>
	<brief_summary>In subjects on boosted protease inhibitor (PI)-regimens who have elevated triglycerides, a switch to fosamprenavir/ritonavir once daily followed by the addition of Lovaza will result in 30% of patients achieving a reduction in fasting triglycerides &lt; 200 mg /dL while maintaining virologic suppression.</brief_summary>
	<brief_title>Boosted Lexiva With Lovaza Adjunctive Therapy in Hypertriglyceridemic, HIV-Infected Subjects</brief_title>
	<detailed_description />
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Hypertriglyceridemia</mesh_term>
	<mesh_term>Ritonavir</mesh_term>
	<mesh_term>Fosamprenavir</mesh_term>
	<criteria>fasting triglycerides &gt;= 200 mg/dL but &lt;1,200 mg/dL fasting LDL &lt;= 160 mg/dL participation in a lipidlowering diet and exercise program for at least 28 days treatment with stable HAART consisting of first or second RTVboosted PI regimen plus optimized background ART for at least 3 months plasma HIV1 RNA &lt;50 copies/mL CD4+ cell count &gt;50 cells/mm3 male subjection testosterone replacement therapy with total testosterone level &lt;= 1 x upper limit of normal female study volunteer must use a form of contraception ability and willing ness to give written informed consent any Grade 4 laboratory abnormality currently taking amprenavir or fosamprenavir required a second RTVboosted PI for reasons of virologic failure atherosclerotic disease risk congestive heart failure (NYHA Class III or IV) uncontrolled hypertension history of pancreatitis active bleeding disorder recent history of significant renal, pulmonary, biliary, hepatic or gastrointestinal disease current diabetes mellitus requiring pharmacological treatment use of systemic cancer chemotherapy; active cancer pregnancy or breastfeeding requirement for any lipidlowering agent after baseline use of hormonal anabolic therapies, systemic steroids, immune modulators use of anticoagulants, investigational antiretroviral drugs allergy to study drugs active CDC clinical category C event</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>HIV</keyword>
	<keyword>triglycerides</keyword>
	<keyword>fosamprenavir</keyword>
</DOC>